Literature DB >> 28754453

Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium.

Mario Strazzabosco1, Romina Fiorotto2, Massimiliano Cadamuro3, Carlo Spirli2, Valeria Mariotti4, Eleanna Kaffe4, Roberto Scirpo5, Luca Fabris6.   

Abstract

The most studied physiological function of biliary epithelial cells (cholangiocytes) is to regulate bile flow and composition, in particular the hydration and alkalinity of the primary bile secreted by hepatocytes. After almost three decades of studies it is now become clear that cholangiocytes are also involved in epithelial innate immunity, in inflammation, and in the reparative processes in response to liver damage. An increasing number of evidence highlights the ability of cholangiocyte to undergo changes in phenotype and function in response to liver damage. By participating actively to the immune and inflammatory responses, cholangiocytes represent a first defense line against liver injury from different causes. Indeed, cholangiocytes express a number of receptors able to recognize pathogen- or damage-associated molecular patterns (PAMPs/DAMPs), such as Toll-like receptors (TLR), which modulate their pro-inflammatory behavior. Cholangiocytes can be both the targets and the initiators of the inflammatory process. Derangements of the signals controlling these mechanisms are at the basis of the pathogenesis of different cholangiopathies, both hereditary and acquired, such as cystic fibrosis-related liver disease and sclerosing cholangitis. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cholangiocytes; Cytokines; Inflammasome; Inflammation; Toll-like receptor

Mesh:

Substances:

Year:  2017        PMID: 28754453      PMCID: PMC5785585          DOI: 10.1016/j.bbadis.2017.07.023

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  59 in total

Review 1.  Polycystic liver diseases: congenital disorders of cholangiocyte signaling.

Authors:  Mario Strazzabosco; Stefan Somlo
Journal:  Gastroenterology       Date:  2011-04-22       Impact factor: 22.682

2.  Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis.

Authors:  Serge J Zweers; Alexey Shiryaev; Mina Komuta; Mette Vesterhus; Johannes R Hov; María J Perugorria; D Rudi de Waart; Jung-Chin Chang; Shanna Tol; Anje A Te Velde; Wouter J de Jonge; Jesus M Banales; Tania Roskams; Ulrich Beuers; Tom H Karlsen; Peter L Jansen; Frank G Schaap
Journal:  Liver Int       Date:  2016-03-16       Impact factor: 5.828

Review 3.  Sclerosing cholangitis epidemiology and etiology.

Authors:  Konstantinos N Lazaridis
Journal:  J Gastrointest Surg       Date:  2007-10-24       Impact factor: 3.452

4.  Rat bile as a convenient source of secretory IgA and free secretory component.

Authors:  I Lemaître-Coelho; G D Jackson; J P Vaerman
Journal:  Eur J Immunol       Date:  1977-08       Impact factor: 5.532

5.  Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB.

Authors:  Xian-Ming Chen; Steven P O'Hara; Jeremy B Nelson; Patrick L Splinter; Aaron J Small; Pamela S Tietz; Andrew H Limper; Nicholas F LaRusso
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 6.  Update on primary sclerosing cholangitis.

Authors:  Tom H Karlsen; Erik Schrumpf; Kirsten M Boberg
Journal:  Dig Liver Dis       Date:  2010-02-20       Impact factor: 4.088

Review 7.  Primary sclerosing cholangitis.

Authors:  Y M Lee; M M Kaplan
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

8.  Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis.

Authors:  Tobias Mueller; Claudia Beutler; Almudena Hurtado Picó; Oren Shibolet; Daniel S Pratt; Andreas Pascher; Peter Neuhaus; Bertram Wiedenmann; Thomas Berg; Daniel K Podolsky
Journal:  Liver Int       Date:  2011-09-15       Impact factor: 5.828

9.  Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia.

Authors:  Kenichi Harada; Yasunori Sato; Keita Itatsu; Kumiko Isse; Hiroko Ikeda; Mitsue Yasoshima; Yoh Zen; Akira Matsui; Yasuni Nakanuma
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

10.  Long-term culture of genome-stable bipotent stem cells from adult human liver.

Authors:  Meritxell Huch; Helmuth Gehart; Ruben van Boxtel; Karien Hamer; Francis Blokzijl; Monique M A Verstegen; Ewa Ellis; Martien van Wenum; Sabine A Fuchs; Joep de Ligt; Marc van de Wetering; Nobuo Sasaki; Susanne J Boers; Hans Kemperman; Jeroen de Jonge; Jan N M Ijzermans; Edward E S Nieuwenhuis; Ruurdtje Hoekstra; Stephen Strom; Robert R G Vries; Luc J W van der Laan; Edwin Cuppen; Hans Clevers
Journal:  Cell       Date:  2014-12-18       Impact factor: 41.582

View more
  17 in total

Review 1.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

Review 2.  Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-05       Impact factor: 5.187

3.  Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.

Authors:  Maria Eugenia Guicciardi; Christy E Trussoni; Anuradha Krishnan; Steven F Bronk; Maria J Lorenzo Pisarello; Steven P O'Hara; Patrick L Splinter; Yandong Gao; Pamela Vig; Alexander Revzin; Nicholas F LaRusso; Gregory J Gores
Journal:  J Hepatol       Date:  2018-05-24       Impact factor: 25.083

Review 4.  Animal models for cystic fibrosis liver disease (CFLD).

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Massimiliano Cadamuro; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-07-30       Impact factor: 5.187

Review 5.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

Review 6.  Bile acids and their receptors: modulators and therapeutic targets in liver inflammation.

Authors:  Anna Bertolini; Romina Fiorotto; Mario Strazzabosco
Journal:  Semin Immunopathol       Date:  2022-04-12       Impact factor: 11.759

Review 7.  Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota.

Authors:  Romina Fiorotto; Mario Strazzabosco
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-05-07

Review 8.  Beneficial and Deleterious Effects of Female Sex Hormones, Oral Contraceptives, and Phytoestrogens by Immunomodulation on the Liver.

Authors:  Luis E Soria-Jasso; Raquel Cariño-Cortés; Víctor Manuel Muñoz-Pérez; Elizabeth Pérez-Hernández; Nury Pérez-Hernández; Eduardo Fernández-Martínez
Journal:  Int J Mol Sci       Date:  2019-09-22       Impact factor: 5.923

Review 9.  New insights on the role of vascular endothelial growth factor in biliary pathophysiology.

Authors:  Valeria Mariotti; Romina Fiorotto; Massimiliano Cadamuro; Luca Fabris; Mario Strazzabosco
Journal:  JHEP Rep       Date:  2021-02-04

Review 10.  Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.

Authors:  Mette Vesterhus; Tom Hemming Karlsen
Journal:  J Gastroenterol       Date:  2020-03-28       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.